A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

January 22, 2019

Primary Completion Date

July 29, 2020

Study Completion Date

July 29, 2020

Conditions
Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality
Interventions
DEVICE

JUVÉDERM®

Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).

DRUG

BOTOX Cosmetic®

BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).

DRUG

BELKYRA®

BELKYRA, subcutaneous injection for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose = 100 mg (10mL).

OTHER

SkinMedica

SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).

Trial Locations (7)

BC V5Z 4E1

Carruthers & Humphrey Cosmetic Dermatology, Vancouver

Shannon Humphrey, Vancouver

BC V6H 1K9

Project Skin MD Vancouver, Vancouver

BC V6H 4E1

Pacific Derm, Vancouver

ON L7N 3N2

Dermetics, Burlington

ON M5R 3N8

Dr Nowell Solish, Toronto

ON L4L 8E2

Bertucci MedSpa, Woodbridge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT03712449 - A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment | Biotech Hunter | Biotech Hunter